Risk evaluation mitigation strategy: impact of application of the Food and Drug Adminstration's strategy on use of erythropoiesis‐stimulating agents and transfusion in patients with chemotherapy‐induced anaemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2710|40|3|299-303

ISSN： 0269-4727

Source： JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol.40, Iss.3, 2015-06, pp. : 299-303

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Potential Health Economic Impact of Intravenous Iron Supplementation to Erythropoiesis-Stimulating Agent Treatment in Patients with Cancer- or Chemotherapy-Induced Anemia

By  

Oncology, Vol. 81, Iss. 1, 2011-09 ,pp. : 45-49

Karger

Access to resources Recommend Favorite

Use and cost of erythropoiesis-stimulating agents in patients with cancer

By Daniel Gregory   Hurley Dana   Whyte Joanna L.   Willey Vincent   Wilson Marcus   Kallich Joel  

Current Medical Research and Opinion, Vol. 25, Iss. 7, 2009-07 ,pp. : 1775-1784

Informa Healthcare

Access to resources Recommend Favorite

Evaluation and Determinants of Underprescription of Erythropoiesis Stimulating Agents in Pre-Dialysis Patients with Anaemia

By  

Nephron Clin Pract, Vol. 108, Iss. 1, 2008-01 ,pp. : c67-c74

Karger

Access to resources Recommend Favorite

Treatment of Anaemia with Erythropoiesis-Stimulating Agents in Patients with Chronic Kidney Disease Does Not Lower Mortality and May Increase Cardiovascular Risk: A Meta-Analysis

By  

Nephron Clin Pract, Vol. 121, Iss. 3-4, 2012-11 ,pp. : c95-c101

Karger

Access to resources Recommend Favorite

Treatment of renal anaemia with erythropoiesis‐stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis

By  

NEPHROLOGY, Vol. 20, Iss. S4, 2015-12 ,pp. : 29-32

John Wiley & Sons Inc

Access to resources Recommend Favorite